Horizontal Alveolar Bone LossPVDF + HRANCT07095530
Horizontal Ridge Augmentation Using Polyvinylidene Fluoride Versus Titanium Mesh Membranes
A study testing titanium membrane in people with Horizontal Alveolar Bone Loss, run by Minia University at 1 site in Egypt.
Trial summary
This study aims to evaluate the effectiveness of a new PVDF non-resorbable membrane versus Titanium Mesh in the treatment of horizontal ridge defects prepared for implant placement Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Horizontal Alveolar Bone Loss
- What is being tested?
- titanium membrane
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 42 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2024to 20 Jan 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- All patients were diagnosed with Class I (Horizontal ridge deficiency) according to Seibert's classification of alveolar ridge deficiencies (Seibert, 1983) .Maxilla and mandible partial edentulism, not more than 2 teeth missing with D3, D4 bone density(Smith \& Zarb, 1989).
- Presence of a horizontally deficient edentulous ridge (Low < 5 mm) (Misch et al., 2021).
- Good systemic health (ASA I ) (Böhmer et al., 2021).
- Patients aged 18-55 years.
- Non-smokers or light smokers (<10 cigarettes/day).
Who cannot join
- Poor oral hygiene with BOP > 20%.
- Heavy smoking (more than 10 cigarettes per day).
- local and systemic acute infection.
- Patients who received radiotherapy in the head and neck within the previous five years.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Horizontal Ridge Augmentation Using Polyvinylidene Fluoride Versus Titanium Mesh Membranes - A Randomized Clinical Trial
This study aims to evaluate the effectiveness of a new PVDF non-resorbable membrane versus Titanium Mesh in the treatment of horizontal ridge defects prepared for implant placement
Read the detailed description
Alveolar ridge resorption following tooth loss frequently results in horizontal deficiencies that complicate optimal implant placement. To address this, guided bone regeneration (GBR) techniques have become standard in clinical practice, relying on barrier membranes to stabilize graft material and exclude soft tissue interference during healing Titanium mesh membranes have been widely utilized in GBR due to their excellent mechanical strength and ability to maintain space in large or complex defects. Their rigidity ensures stability of the graft material, promoting favorable bone regeneration outcomes. However, the stiffness of titanium meshes can lead to complications such as soft tissue dehiscence and membrane exposure, potentially compromising the regenerative process On the other hand, polyvinylidene fluoride (PVDF) membranes have emerged as a promising alternative in GBR procedures. PVDF is a biocompatible, chemically stable polymer known for its flexibility and resistance to bacterial colonization. Its pliable nature allows for better adaptation to the defect site, potentially reducing the risk of membrane exposure and associated complications. Additionally, the smooth surface of PVDF membranes may minimize soft tissue irritation, further enhancing healing outcomes Materials and methods Study design and patient selection This study was designed as a randomized, controlled, parallel-arm, triple-blinded clinical trial aimed at rigorously comparing the clinical and radiographic outcomes of ridge augmentation procedures utilizing two distinct materials: titanium mesh and high-density polyvinylidene fluoride (PVDF) membrane. In this trial, participants, clinical outcome assessors, and statisticians were kept blind to the treatments being administered to mitigate bias. However, due to the inherent nature of the surgical procedures involved, the operating surgeon could not be blinded.
Participants were selected from the outpatient clinic at the Department of Oral Medicine, Oral Diagnosis, and Periodontology at the Faculty of Dentistry, Nahda University, Beni Suef, Egypt. Inclusion criteria were clearly defined, ensuring that only eligible candidates participated in the study. Prior to enrollment, written informed consent was meticulously obtained from all participants after providing a thorough explanation of the experimental procedures, potential risks, and anticipated benefits associated with their involvement in the research.
The study was conducted in strict adherence to the ethical principles outlined in the Declaration of Helsinki. Additionally, it complied with the International Conference on Harmonization Good Clinical Practice Guidelines. The Research Ethics Committee at the Faculty of Dentistry, Minia University, Minia, Egypt, granted approval for the study, which was registered under a specific registration number ( ) to ensure compliance and transparency in the research process. (clinical trial registration number) 2.2 | Patient Selection
Patient selection underwent stringent selection criteria as follows:
Inclusion criteria:
- All patients were diagnosed with Class I (Horizontal ridge deficiency) according to Seibert's classification of alveolar ridge deficiencies
- Maxilla and mandible partial edentulism, not more than 2 teeth missing with D3, D4 bone density (5) Patients aged 18-55 years. (6) Non-smokers or light smokers (<10 cigarettes/day).
Exclusion Criteria:
(1) Poor oral hygiene with BOP > 20%. (4) Uncontrolled systemic diseases. (5) local and systemic acute infection. (6) Patients who received radiotherapy in the head and neck within the previous five years.
(7) patients with stage III or IV. Randomization and Allocation A total of forty-two participants were randomly allocated in a 1:1 ratio into two distinct groups. The control group (n = 21) received a Titanium mesh membrane, which was covered with a collagen membrane, while the study group (n = 21) was treated with a Polyvinylidene fluoride (PVDF) membrane.
Participants were randomized using a computer-generated method (www.random.org ), ensuring an unbiased distribution of subjects into each group. An independent researcher meticulously oversaw this process to maintain the integrity of the trial. To further safeguard against bias, allocation concealment was rigorously implemented through the use of sealed, opaque envelopes, which secured the treatment assignments until the point of implementation. This comprehensive approach aimed to enhance the validity and reliability of the research findings.
Membrane Preparation Materials: (DMF), using an 80:20 weight ratio of PVDF to PVP. Specifically, 8 grams of PVDF and 2 grams of PVP were added to 90 milliliters of DMF under continuous magnetic stirring at room temperature overnight to ensure complete dissolution and the formation of a uniform solution.
2.6 | Clinical and radiographic assessment All parameters were assessed by the same blinded examiner (A.G) twice: at baseline before surgery (T0) and again after membrane exposure (T1). Data were collected using a specific data collection form.
The primary outcome measured was horizontal bone gain (HBG) (Figure 3a\& 6a), determined from a CBCT radiograph taken with the same machine (SCANORA® 3Dx CBCT scanner, Finland). This measurement was evaluated 2 mm below the highest crestal point. At baseline and six months after surgery, the difference between the two measurements was calculated using the formula: HBG (mm) = Postoperative width - Preoperative width.
Secondary outcomes included: the keratinized tissue thickness (KTT), which was measured using an endodontic file No. 8 with a 3 mm diameter silicon stopper. The thickness of the soft tissues was assessed 2 mm apically to the gingival margin. The file was carefully inserted through the soft tissues until a hard surface was felt, keeping it perpendicular to the mucosal surface. Following this, the silicone disk was positioned closely after the file was gently removed from contact with the soft tissue surface, and the penetration depth was then measured (Zucchelli et al., 2013).
Healing complications (HC) were measured, which are classified according to (Fontana et al., 2011) into Class I: No purulent exudate with small membrane exposure (≤ 3 mm), Class II: No purulent exudate with large membrane exposure (> 3 mm), Class III: Both membrane exposure and purulent exudate occur, Class IV: Abscess development without exposure of the membrane. Also, exposure detection could be categorized into early (throughout the first month) or late (after the first month).
Membrane exposure rate (MER): early exposure, before one month (3-29 days), and late exposure, after one month (1-8 months) .
Pseudo-Periosteum Identified (PPI): This parameter was measured at (T1) and classified into Type 1: Typical dense and fibrous, either no tissue or less than 1 mm thick. Type 2: Tissue has moderate consistency and thickness, ranging from 1 to 2 mm. Type 3: Unusual tissue is denser than 2 mm, often vascularized, and has a loose texture Surgical complications (SC) were taken during (T0) A: Inability to close the surgical flaps with the primary intention. B: Flap perforation or laceration. C: Vascular complications: Bleeding after surgery, edema. D: Neurologic complications: Nerve injury during surgery (Fontana et al., 2011).
The flap was closed using a tension-free suture technique that combined horizontal mattress sutures and interrupted sutures, utilizing a 5-0 polypropylene suture (polypropylene monofilament from the industrial zone in Borg El Arab, El Gedida, Alex City, Egypt)
- Conditions
- Horizontal Alveolar Bone Loss
- Being tested
- titanium membrane
- Keywords
- Horizontal ridge augmentation, PVDF, Titanium Mesh
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
titanium membraneProcedure or surgery
Also called PVDF membrane, titanium mesh, xenograft bone, collagen membrane
surgical treatment for horizontal ridge augmentation by titanium mesh and PVDF membrane
| Study group | Role | What they receive |
|---|---|---|
| control group | Placebo comparator | This study conducted two main surgical interventions: (T0) one for bone reconstruction and (T1) another for membrane removal following exposure. During the first surgery (T0), patients rinsed with a 0.2% chlorhexidine mouthwash (Eva Pharma, Giza, Egypt) for 60 seconds. All selected sites were anesthetized using articaine hydrochloride 4% with adrenaline (1:100,000) (Artinibsa, Inibsa Spain, Wedjat Pharma). A mid-crestal incision was made, extending to a sulcular incision of adjacent teeth, which included one mesial tooth and two distal teeth. In the edentulous area, the flap extended 3-4 mm posterior to the defect site, along with two vertical releasing incisions. A full-thickness mucoperiosteal flap was raised with a mucoperiosteal elevator (Molt Elevator No. 9, Hu-Friedy®, Hu-Friedy Mfg. Co., LLC. USA) to expose the defect site and adjacent bone; the buccal flap extended apically 5 mm beyond the defect site with a periosteal releasing incision (PRI) for flap mov Receives: Procedure: titanium membrane |
| study group | Active comparator | This study conducted two main surgical interventions: (T0) one for bone reconstruction and (T1) another for membrane removal following exposure. During the first surgery (T0), patients rinsed with a 0.2% chlorhexidine mouthwash (Eva Pharma, Giza, Egypt) for 60 seconds. All selected sites were anesthetized using articaine hydrochloride 4% with adrenaline (1:100,000) (Artinibsa, Inibsa Spain, Wedjat Pharma). A mid-crestal incision was made, extending to a sulcular incision of adjacent teeth, which included one mesial tooth and two distal teeth. In the edentulous area, the flap extended 3-4 mm posterior to the defect site, along with two vertical releasing incisions. A full-thickness mucoperiosteal flap was raised with a mucoperiosteal elevator (Molt Elevator No. 9, Hu-Friedy®, Hu-Friedy Mfg. Co., LLC. USA) to expose the defect site and adjacent bone; the buccal flap extended apically 5 mm beyond the defect site with a periosteal releasing incision (PRI) for flap mov Receives: Procedure: titanium membrane |
What is being measured
The primary outcome is the main question the study is designed to answer.
horizontal ridge augmentation
determined from a CBCT radiograph taken with the same machine (SCANORA® 3Dx CBCT scanner, Finland). This measurement was evaluated 2 mm below the highest crestal point. At baseline and six months after surgery, the difference between the two measurements was calculated using the formula: HBG (mm) = Postoperative width - Preoperative width.
Measured: After 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2025
- Study start1 Jun 2024
- Primary completion17 Jan 2025
- Study completion20 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Horizontal Alveolar Bone LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A total of forty-two participants were randomly allocated in a 1:1 ratio into two distinct groups. The control group (n = 21) received a Titanium mesh membrane, which was covered with a collagen membrane, while the study group (n = 21) was treated with a Polyvinylidene fluoride (PVDF) membrane. Participants were randomized using a computer-generated method (www.random.org ), ensuring an unbiased distribution of subjects into each group. This process was meticulously overseen by an independent researcher to maintain the integrity of the trial. To further safeguard against bias, allocation concealment was rigorously implemented through the use of sealed, opaque envelopes, which secured the treatment assignments until the point of implementation. This comprehensive approach aimed to enhance the validity and reliability of the research findings.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, shaimaa hamdy, Minia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07095530
- Sponsor's protocol ID
- PVDF membrane in HRA
- Other IDs
- committee 1059
- Acronym
- PVDF + HRA
- Status last verified
- Jul 2025
- First submitted
- 4 Jul 2025
- Last updated
- 31 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: After publishing, i will share IPD
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Horizontal Ridge Augmentation Using Polyvinylidene Fluoride Versus Titanium Mesh Membranes - A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07095530
- Acronym / sponsor ID
- PVDF + HRA / PVDF membrane in HRA
- Conditions
- Horizontal Alveolar Bone Loss
- Keywords
- Horizontal ridge augmentation, PVDF, Titanium Mesh
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 17 Jan 2025 (actual)
- Study completion
- 20 Jan 2025 (actual)
- First posted
- 31 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effectiveness of a new PVDF non-resorbable membrane versus Titanium Mesh in the treatment of horizontal ridge defects prepared for implant placement
Detailed description
Alveolar ridge resorption following tooth loss frequently results in horizontal deficiencies that complicate optimal implant placement. To address this, guided bone regeneration (GBR) techniques have become standard in clinical practice, relying on barrier membranes to stabilize graft material and exclude soft tissue interference during healing Titanium mesh membranes have been widely utilized in GBR due to their excellent mechanical strength and ability to maintain space in large or complex defects. Their rigidity ensures stability of the graft material, promoting favorable bone regeneration outcomes. However, the stiffness of titanium meshes can lead to complications such as soft tissue dehiscence and membrane exposure, potentially compromising the regenerative process On the other hand, polyvinylidene fluoride (PVDF) membranes have emerged as a promising alternative in GBR procedures. PVDF is a biocompatible, chemically stable polymer known for its flexibility and resistance to bacterial colonization. Its pliable nature allows for better adaptation to the defect site, potentially reducing the risk of membrane exposure and associated complications. Additionally, the smooth surface of PVDF membranes may minimize soft tissue irritation, further enhancing healing outcomes Materials and methods Study design and patient selection This study was designed as a randomized, controlled, parallel-arm, triple-blinded clinical trial aimed at rigorously comparing the clinical and radiographic outcomes of ridge augmentation procedures utilizing two distinct materials: titanium mesh and high-density polyvinylidene fluoride (PVDF) membrane. In this trial, participants, clinical outcome assessors, and statisticians were kept blind to the treatments being administered to mitigate bias. However, due to the inherent nature of the surgical procedures involved, the operating surgeon could not be blinded.
Participants were selected from the outpatient clinic at the Department of Oral Medicine, Oral Diagnosis, and Periodontology at the Faculty of Dentistry, Nahda University, Beni Suef, Egypt. Inclusion criteria were clearly defined, ensuring that only eligible candidates participated in the study. Prior to enrollment, written informed consent was meticulously obtained from all participants after providing a thorough explanation of the experimental procedures, potential risks, and anticipated benefits associated with their involvement in the research.
The study was conducted in strict adherence to the ethical principles outlined in the Declaration of Helsinki. Additionally, it complied with the International Conference on Harmonization Good Clinical Practice Guidelines. The Research Ethics Committee at the Faculty of Dentistry, Minia University, Minia, Egypt, granted approval for the study, which was registered under a specific registration number ( ) to ensure compliance and transparency in the research process. (clinical trial registration number) 2.2 | Patient Selection
Patient selection underwent stringent selection criteria as follows:
Inclusion criteria:
- All patients were diagnosed with Class I (Horizontal ridge deficiency) according to Seibert's classification of alveolar ridge deficiencies
- Maxilla and mandible partial edentulism, not more than 2 teeth missing with D3, D4 bone density (5) Patients aged 18-55 years. (6) Non-smokers or light smokers (<10 cigarettes/day).
Exclusion Criteria:
(1) Poor oral hygiene with BOP > 20%. (4) Uncontrolled systemic diseases. (5) local and systemic acute infection. (6) Patients who received radiotherapy in the head and neck within the previous five years.
(7) patients with stage III or IV. Randomization and Allocation A total of forty-two participants were randomly allocated in a 1:1 ratio into two distinct groups. The control group (n = 21) received a Titanium mesh membrane, which was covered with a collagen membrane, while the study group (n = 21) was treated with a Polyvinylidene fluoride (PVDF) membrane.
Participants were randomized using a computer-generated method (www.random.org ), ensuring an unbiased distribution of subjects into each group. An independent researcher meticulously oversaw this process to maintain the integrity of the trial. To further safeguard against bias, allocation concealment was rigorously implemented through the use of sealed, opaque envelopes, which secured the treatment assignments until the point of implementation. This comprehensive approach aimed to enhance the validity and reliability of the research findings.
Membrane Preparation Materials: (DMF), using an 80:20 weight ratio of PVDF to PVP. Specifically, 8 grams of PVDF and 2 grams of PVP were added to 90 milliliters of DMF under continuous magnetic stirring at room temperature overnight to ensure complete dissolution and the formation of a uniform solution.
2.6 | Clinical and radiographic assessment All parameters were assessed by the same blinded examiner (A.G) twice: at baseline before surgery (T0) and again after membrane exposure (T1). Data were collected using a specific data collection form.
The primary outcome measured was horizontal bone gain (HBG) (Figure 3a\& 6a), determined from a CBCT radiograph taken with the same machine (SCANORA® 3Dx CBCT scanner, Finland). This measurement was evaluated 2 mm below the highest crestal point. At baseline and six months after surgery, the difference between the two measurements was calculated using the formula: HBG (mm) = Postoperative width - Preoperative width.
Secondary outcomes included: the keratinized tissue thickness (KTT), which was measured using an endodontic file No. 8 with a 3 mm diameter silicon stopper. The thickness of the soft tissues was assessed 2 mm apically to the gingival margin. The file was carefully inserted through the soft tissues until a hard surface was felt, keeping it perpendicular to the mucosal surface. Following this, the silicone disk was positioned closely after the file was gently removed from contact with the soft tissue surface, and the penetration depth was then measured (Zucchelli et al., 2013).
Healing complications (HC) were measured, which are classified according to (Fontana et al., 2011) into Class I: No purulent exudate with small membrane exposure (≤ 3 mm), Class II: No purulent exudate with large membrane exposure (> 3 mm), Class III: Both membrane exposure and purulent exudate occur, Class IV: Abscess development without exposure of the membrane. Also, exposure detection could be categorized into early (throughout the first month) or late (after the first month).
Membrane exposure rate (MER): early exposure, before one month (3-29 days), and late exposure, after one month (1-8 months) .
Pseudo-Periosteum Identified (PPI): This parameter was measured at (T1) and classified into Type 1: Typical dense and fibrous, either no tissue or less than 1 mm thick. Type 2: Tissue has moderate consistency and thickness, ranging from 1 to 2 mm. Type 3: Unusual tissue is denser than 2 mm, often vascularized, and has a loose texture Surgical complications (SC) were taken during (T0) A: Inability to close the surgical flaps with the primary intention. B: Flap perforation or laceration. C: Vascular complications: Bleeding after surgery, edema. D: Neurologic complications: Nerve injury during surgery (Fontana et al., 2011).
The flap was closed using a tension-free suture technique that combined horizontal mattress sutures and interrupted sutures, utilizing a 5-0 polypropylene suture (polypropylene monofilament from the industrial zone in Borg El Arab, El Gedida, Alex City, Egypt)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- A total of forty-two participants were randomly allocated in a 1:1 ratio into two distinct groups. The control group (n = 21) received a Titanium mesh membrane, which was covered with a collagen membrane, while the study group (n = 21) was treated with a Polyvinylidene fluoride (PVDF) membrane. Participants were randomized using a computer-generated method (www.random.org ), ensuring an unbiased distribution of subjects into each group. This process was meticulously overseen by an independent researcher to maintain the integrity of the trial. To further safeguard against bias, allocation concealment was rigorously implemented through the use of sealed, opaque envelopes, which secured the treatment assignments until the point of implementation. This comprehensive approach aimed to enhance the validity and reliability of the research findings.
| Arm | Type | Receives |
|---|---|---|
| control group | Placebo comparator | Procedure: titanium membraneThis study conducted two main surgical interventions: (T0) one for bone reconstruction and (T1) another for membrane removal following exposure. During the first surgery (T0), patients rinsed with a 0.2% chlorhexidine mouthwash (Eva Pharma, Giza, Egypt) for 60 seconds. All selected sites were anesthetized using articaine hydrochloride 4% with adrenaline (1:100,000) (Artinibsa, Inibsa Spain, Wedjat Pharma). A mid-crestal incision was made, extending to a sulcular incision of adjacent teeth, which included one mesial tooth and two distal teeth. In the edentulous area, the flap extended 3-4 mm posterior to the defect site, along with two vertical releasing incisions. A full-thickness mucoperiosteal flap was raised with a mucoperiosteal elevator (Molt Elevator No. 9, Hu-Friedy®, Hu-Friedy Mfg. Co., LLC. USA) to expose the defect site and adjacent bone; the buccal flap extended apically 5 mm beyond the defect site with a periosteal releasing incision (PRI) for flap mov |
| study group | Active comparator | Procedure: titanium membraneThis study conducted two main surgical interventions: (T0) one for bone reconstruction and (T1) another for membrane removal following exposure. During the first surgery (T0), patients rinsed with a 0.2% chlorhexidine mouthwash (Eva Pharma, Giza, Egypt) for 60 seconds. All selected sites were anesthetized using articaine hydrochloride 4% with adrenaline (1:100,000) (Artinibsa, Inibsa Spain, Wedjat Pharma). A mid-crestal incision was made, extending to a sulcular incision of adjacent teeth, which included one mesial tooth and two distal teeth. In the edentulous area, the flap extended 3-4 mm posterior to the defect site, along with two vertical releasing incisions. A full-thickness mucoperiosteal flap was raised with a mucoperiosteal elevator (Molt Elevator No. 9, Hu-Friedy®, Hu-Friedy Mfg. Co., LLC. USA) to expose the defect site and adjacent bone; the buccal flap extended apically 5 mm beyond the defect site with a periosteal releasing incision (PRI) for flap mov |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- All patients were diagnosed with Class I (Horizontal ridge deficiency) according to Seibert's classification of alveolar ridge deficiencies (Seibert, 1983) .Maxilla and mandible partial edentulism, not more than 2 teeth missing with D3, D4 bone density(Smith \& Zarb, 1989).
- Presence of a horizontally deficient edentulous ridge (Low < 5 mm) (Misch et al., 2021).
- Good systemic health (ASA I ) (Böhmer et al., 2021).
- Patients aged 18-55 years.
- Non-smokers or light smokers (<10 cigarettes/day).
Key exclusion criteria (4 listed)
- Poor oral hygiene with BOP > 20%.
- Heavy smoking (more than 10 cigarettes per day).
- local and systemic acute infection.
- Patients who received radiotherapy in the head and neck within the previous five years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| titanium membraneAlso: PVDF membrane, titanium mesh, xenograft bone, collagen membranesurgical treatment for horizontal ridge augmentation by titanium mesh and PVDF membrane | Procedure or surgery | control group, study group |
Primary outcome
horizontal ridge augmentation
Time frame: After 6 months
determined from a CBCT radiograph taken with the same machine (SCANORA® 3Dx CBCT scanner, Finland). This measurement was evaluated 2 mm below the highest crestal point. At baseline and six months after surgery, the difference between the two measurements was calculated using the formula: HBG (mm) = Postoperative width - Preoperative width.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. After publishing, i will share IPD
Related trials for Horizontal Alveolar Bone Loss
Enrolling by invitation
Investigation of the Effect of Horizontal Platelet Rich Fibrin Placed in Tooth Extraction Sockets on Bone Formation
Tooth Loss, Dental Implant Failed
Not yet recruiting
Autogenous and Xenograft Bone Mix in Alveolar Ridge Reconstruction
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Comparison of Three Autogenous Bone and Xenograft Ratios for Horizontal Ridge Augmentation
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Comparison of Two Autogenous Bone and Xenograft Ratios for Horizontal Ridge Augmentation
Horizontal Alveolar Ridge Deficiency
Recruiting
Histological and Histomorphometric Assessment With Inflammatory Profile Analysis of Bone Tissue After Horizontal Ridge Augmentation Using Customized Porous Zirconia Shell
Alveolar Bone Loss, Alveolar Ridge Deficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing titanium membrane in people with Horizontal Alveolar Bone Loss, run by Minia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
horizontal ridge augmentation (time frame: After 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2025.